| 000 | 01762 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516074317.0 | ||
| 264 | 0 | _c20130603 | |
| 008 | 201306s 0 0 eng d | ||
| 022 | _a1880-0920 | ||
| 024 | 7 |
_a10.2133/dmpk.dmpk-11-rg-134 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTakashina, Yoshiaki | |
| 245 | 0 | 0 |
_aImpact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. _h[electronic resource] |
| 260 |
_bDrug metabolism and pharmacokinetics _c2012 |
||
| 300 |
_a414-21 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aATP Binding Cassette Transporter, Subfamily B |
| 650 | 0 | 4 |
_aATP Binding Cassette Transporter, Subfamily B, Member 1 _xgenetics |
| 650 | 0 | 4 | _aAdministration, Cutaneous |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnalgesics, Opioid _xadministration & dosage |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A _xgenetics |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFentanyl _xadministration & dosage |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aJapan |
| 650 | 0 | 4 | _aLogistic Models |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aOdds Ratio |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 700 | 1 | _aNaito, Takafumi | |
| 700 | 1 | _aMino, Yasuaki | |
| 700 | 1 | _aYagi, Tatsuya | |
| 700 | 1 | _aOhnishi, Kazunori | |
| 700 | 1 | _aKawakami, Junichi | |
| 773 | 0 |
_tDrug metabolism and pharmacokinetics _gvol. 27 _gno. 4 _gp. 414-21 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2133/dmpk.dmpk-11-rg-134 _zAvailable from publisher's website |
| 999 |
_c21491623 _d21491623 |
||